$HAE News

Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Baird Maintains Outperform on Haemonetics, Raises Price Target to $119

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $118

Haemonetics Shares Hit New 52-Week High: What's Happening?

BTIG Maintains Buy on Haemonetics, Raises Price Target to $110

Haemonetics To Supply CSL Plasma With Its NexSys PCS Devices With Persona PLUS Technology And Allow Purchases Of Related Disposables In The U.S.; Agreement Is Non-Exclusive And With No Minimum Purchase Commitments

Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance

Haemonetics (HAE) Earnings Beat Puts Fair Value Back In Focus

Haemonetics (NYSE:HAE) Shines in Quality Investing Screen

5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call

Haemonetics (HAE) Q1 2027 Earnings Call Transcript

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady

Haemonetics Q1 Earnings Call Highlights

Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92

JP Morgan Maintains Neutral on Haemonetics, Raises Price Target to $86

Haemonetics Corp (HAE) (Q1 2027) Earnings Call Highlights: Strong Start Drives Raised Guidance

Haemonetics Corporation 2027 Q1 - Results - Earnings Call Presentation

BTIG Maintains Buy on Haemonetics, Raises Price Target to $96